Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Endocyte Targets Folate Receptor Cancers, Devising Innovative Route To Market

Executive Summary

With its cash position bolstered by a pair of public equity offerings this year, Endocyte Inc. is pressing ahead with its novel therapeutic and diagnostic platform, initiating late-stage trials in platinum-resistant ovarian cancer (PROC) and non-small-cell lung cancer (NSCLC), with a plan to seek a first approval in Europe.
Advertisement

Related Content

Synta’s Newest Phase II Results Could Reshape Ganetespib’s Pivotal Data, But Some Remain Skeptical
Synta’s Newest Phase II Results Could Reshape Ganetespib’s Pivotal Data, But Some Analysts Remain Skeptical
Endocyte Back On Track To File Lead Candidate For EU Conditional Approval This Year
Merck Gains Phase III Drug/Companion Diagnostic In Deal With Endocyte
Endocyte Back On Track To File Lead Candidate For EU Conditional Approval This Year
Burrill & Co. Launches Fourth Fund With $313 Million And Aims For More
Endocyte And Accelerated Approval
Endocyte And Accelerated Approval
FDA Will Make Advisory Committee Review Of Accelerated Approvals An Annual Event
Roche's T-DM1 Early Filing Strategy Backfires As FDA Refuses To File BLA

Topics

Advertisement
UsernamePublicRestriction

Register

PS053734

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel